格隆汇10月14日丨清晰医疗(01406.HK)公告，截至2026年财政年度半年度(自2025年3月31日至2025年9 月30日止6个月)，集团录得收益约8500万港元，较去年同期轻微下降不足3%。由于极端恶劣的天气状 况，集团的香港诊所于七月至九月期间停业或严重中断八天。此外，因某前任董事作出的指控而引致的 负面媒体报道或会对集团近几个月的业务造成不利影响。 公司通过与强生的独家合作引进其新一代屈光手术技术SILK™，进一步巩固在香港眼科市场的技术领 先地位。该技术采用低能量、超精准的飞秒激光脉冲，有效地减轻角膜组织损伤和神经损伤，从而实现 更快的恢复和更好的术後效果。作为香港首家及唯一一家提供SILK™技术的机构，公司计划于2025年 第四季度推广该项技术。 公司股份已于2025年4月15日(星期二)上午九时正起暂停在联交所买卖，并将继续暂停买卖，直至进一 步通知。 诚如公司日期为2025年7月14日的季度更新公告所述，有关公司的持续指控阻碍了主要战略计划的执 行，并损害了业务营运。集团承诺将高效地完成有关调查，稳定营运，以便管理层可重新专注于长期战 略重点。 ...

Core Viewpoint - Clear Medical (01406) reported a revenue of approximately HKD 85 million for the first half of the fiscal year ending 2026, reflecting a slight decline of less than 3% compared to the same period last year due to adverse weather conditions and negative media coverage [1] Financial Performance - The company achieved revenues of about HKD 85 million, which is a minor decrease of less than 3% year-on-year [1] - The Hong Kong clinics experienced operational disruptions for eight days from July to September due to extreme weather conditions [1] Business Developments - The company has strengthened its technological leadership in the Hong Kong ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce the new generation refractive surgery technology SILK™ [1] - SILK™ technology utilizes low-energy, ultra-precise femtosecond laser pulses to minimize corneal and nerve tissue damage, leading to faster recovery and improved postoperative outcomes [1] - Clear Medical plans to promote the SILK™ technology in the fourth quarter of 2025, being the first and only institution in Hong Kong to offer this technology [1]